Clinical Trials Logo
  1. Home
  2. Glabellar Rhytides
  3. NCT01814670

Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

Glabellar Rhytides Clinical Trial

Clinical Trial Summary

A study to evaluate safety and efficacy of treatment with botulinum toxin Type A (BOTOX®) in Chinese patients with moderate to severe frown lines (Glabellar Rhytides) previously treated with facial laser resurfacing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01814670
Study type Interventional
Source Allergan
Contact
Status Completed
Phase Phase 4
Start date March 6, 2013
Completion date October 29, 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02261467 - A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides Phase 3
Completed NCT02261493 - A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides Phase 3
Completed NCT00752050 - Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows Phase 3
Completed NCT00752297 - Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows Phase 3
Completed NCT00752258 - A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows Phase 3